January 31, 2022
January, 2023 -
The 2022 U.S. Generic and Biosimilar Medicines Savings Report, published by the Association for Accessible Medicines, found that the U.S.
January 21, 2022
January 21, 2022 –
Selzentry (maraviroc) tablets – for HIV. Adverse reactions or quality problems
January 21, 2022
January 21, 2022 –
The U.S. FDA has expanded approval and emergency use authorization (EUA) for Gilead's Veklury® (remdesivir) to treat COVID-19 in certain high-risk individuals
January 19, 2022
January 19, 2022 –
Mylan Pharmaceuticals, a Viatris company, has recalled one batch of non-interchangeable Semglee® (insulin glargine injection), 100 units/mL (U-100) 3mL
January 14, 2022
January 14, 2022 –
AbbVie's Rinvoq® (upadacitinib) has been approved to treat moderate to severe atopic dermatitis (AD) in patients at least 12 years old who have refractory disease
January 14, 2022
January 14, 2022 –
The U.S. FDA has approved Cibinqo® (abrocitinib) to treat moderate to severe atopic dermatitis in adults who have refractory disease not adequately controlled with other
January 13, 2022
January 13, 2022 –
RyaltrisTM (olopatadine hydrochloride/mometasone furoate monohydrate) nasal spray
has been FDA approved to treat the symptoms of seasonal allergic rhinitis in patients
January 12, 2022
January 12, 2022 –
In a drug safety communication, the U.S. FDA has cautioned that dental problems can occur with buprenorphine products that are taken by dissolving them in the mouth